Compare PCRX & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PCRX | DRUG |
|---|---|---|
| Founded | 2006 | 2019 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Pharmaceuticals and Biotechnology |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 856.4M |
| IPO Year | N/A | N/A |
| Metric | PCRX | DRUG |
|---|---|---|
| Price | $23.05 | $80.67 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 6 |
| Target Price | $35.33 | ★ $106.75 |
| AVG Volume (30 Days) | ★ 775.3K | 120.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $6.21 | N/A |
| Revenue Next Year | $8.26 | N/A |
| P/E Ratio | $48.25 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $18.80 | $23.18 |
| 52 Week High | $27.64 | $123.75 |
| Indicator | PCRX | DRUG |
|---|---|---|
| Relative Strength Index (RSI) | 58.70 | 49.93 |
| Support Level | $20.88 | $74.21 |
| Resistance Level | $21.60 | $84.66 |
| Average True Range (ATR) | 0.80 | 5.51 |
| MACD | 0.39 | 0.31 |
| Stochastic Oscillator | 93.52 | 65.47 |
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.